A Phase 1, Single Centre, Single Dose, Randomised, Double-blind, Two-way Crossover, Glucose Clamp Study Investigating the Pharmacodynamics, Pharmacokinetics, and Safety of Ultra-rapid-acting Concentrated Insulin Aspart AT278 in Comparison to Standard Insulin Aspart NovoRapid With an Additional Open Comparison to Humulin R U-500 in Participants With Type 2 Diabetes
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Insulin aspart (Primary) ; Insulin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Arecor
- 20 May 2024 According to an Arecor media release, Primary endpoint has been met. (Area under the glucose infusion rate-time curve of insulin aspart)
- 20 May 2024 According to an Arecor media release, professor Thomas Pieber is the Principal Investigator of this trial.
- 20 May 2024 According to an Arecor media release, company will host a CEO and key opinion leader webinar to discuss the results on Tuesday 21 May at 14.30 BST